Gilead’s twice-yearly shot cut HIV infections by 96% in trial
The data sets the stage for likely approval of Gilead’s Lenacapavir for HIV prevention.
More Stories
Hard Rock chairman opens the door to a FanDuel or DraftKings partnership in Florida
Hard Rock has the monopoly on sports betting in Florida, winning the exclusive tribal gaming compact after a battle against...
Slotmaker Aristocrat works to protect its IP while moving to a digital future
Aristocrat Gaming CEO Hector Fernandez told CNBC that digital opportunities and protecting intellectual property are key to the company's future.
BetMGM wagers that new technology, football can lead to a resurgence
BetMGM is trying to regain lost ground in both sports gambling and online casino games.
Spirit Halloween to open 10 new ‘Spirit Christmas’ stores catering to holiday shoppers
Spirit Halloween's usual trick-or-treat and go is no longer, as the company announced it will open "Spirit Christmas" locations through...
GM ditching ‘Ultium’ name for batteries, tech amid EV changes
GM confirmed the change ahead of an investor event in which it is expected to tout the flexibility of the...
Boeing delivers 33 jets in September but strike impact looms
Boeing delivered 33 jets but overall deliveries are down on the year.